‘Shine a spotlight on stories of strength': Harry calls for awards nominations
The Duke of Sussex has called on the public to nominate inspirational children and young people with complex medical needs for awards, encouraging them to 'shine a spotlight on the remarkable stories of strength, resilience and courage'.
The WellChild awards annual ceremony celebrates the inspiring qualities of the UK's seriously ill children and young people as well as those who support and care for them.
At last year's event at the Royal Lancaster Hotel in London, Harry hailed a group of 'little legends' for 'uplifting all those around you', with famous faces such as Sir Rod Stewart and his wife Penny Lancaster watching.
Harry, who has been patron of the WellChild charity for more than 15 years, said in a video message on the charity's website: 'The WellChild Awards recognise and celebrate the growing number of young people with complex medical conditions from across the United Kingdom, as well as those who go the extra mile to care for them.
'They allow us to shine a spotlight on the remarkable stories of strength, resilience and courage that they demonstrate every single day. And this year is especially significant as we celebrate the 20th WellChild Awards.
'It is a true privilege to honour the bravery and compassion of this incredible community. And to make this happen, we need your help to nominate the exceptional people who inspire you every single day.
'Your support can make all the difference. Please join us in recognising the amazing individuals who will be honoured at the 2025 WellChild Awards.'
Nominations can be entered online at www.wellchild.org.uk/awards until March 9 and entries will be judged by an expert panel including former winners and child health professionals.
The categories for nominations are: Inspirational Child or Young Person, Inspirational Sibling, Nurse, Outstanding Professional and Inspirational Parent Carer.
The charity's chief executive, Matt James, said: 'This year marks the 20th WellChild Awards, in association with (pharmaceutical giant) GSK, a milestone that highlights more than two decades of celebrating the extraordinary resilience of children and young people in the UK living with long-term, complex medical needs.
'As the number of those facing such challenges continues to grow, the 2025 WellChild Awards provide a unique platform to raise awareness of the immense challenges they face and honour their remarkable spirit.
'They also shine a spotlight on the unwavering dedication of those who support them – from siblings and parent carers to the professionals who go above and beyond to help these remarkable children and young people to thrive.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
Grant funding will be provided to support national, state, and local non-profit organizations and community-based groups focused on lupus New resources and tools will support implementation of community-led programs designed to improve earlier diagnosis, enhance awareness of and access to evidence-based treatment, and/or advance communication between patients and providers Deadline for proposals is September 1, 2025 PHILADELPHIA, June 16, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). "Too many people living with lupus face delays in diagnosis and disconnects in care," said Court Horncastle, Senior Vice President at GSK. "With this initiative, we're proud to support the organizations working within local communities to improve diagnosis, access to optimal care, and connection for those impacted by lupus." GSK is seeking proposals for community-driven initiatives aimed at improving earlier diagnosis and recognition of lupus signs and symptoms; enhancing awareness of and access to evidence-based treatment options; and/or advancing communication between patients and providers regarding lupus. GSK is committing up to $1 million USD in grant funding to support national, state, and local non-profit organizations and community-based groups focused on lupus. This program is in addition to existing funding opportunities GSK provides to support the critical work of partner organizations within the lupus ecosystem. GSK recognizes the pivotal leadership demonstrated by these types of groups and the need to sustain their important work as patient advocates. Eligible organizations should respond to the Call for Grant Applications (CGA) with programming that aligns with the Linked by Lupus: Optimal Care Initiative mission to support people impacted by lupus and help create a sustainable lupus community that fosters a sense of belonging, shared understanding, and mutual support among patients and care partners in the US. Grant proposals are due by September 1, 2025 and will be reviewed and approved according to set principles and criteria. To receive the principles and criteria, please email The grant application process is now open on When submitting your request, please use the following format in your project title: Linked by Lupus: [insert your grant title]. GSK will coordinate regular convenings with external stakeholders and harness existing forums to share best practices in addressing health inequities in lupus, empowering public health organizations and communities with actionable models to help bring successful efforts to scale. More information is available at About GSKGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. Registered in England & Wales:No. 3888792 Registered Office:79 New Oxford StreetLondonWC1A 1DG View source version on Contacts GSK inquiriesMedia:Tim Foley +44 (0) 20 8047 5502 (London)Dan Smith +44 (0) 20 8047 5502 (London)Kathleen Quinn +1 202 603 5003 (Washington DC)Lyndsay Meyer +1 202 302 4595 (Washington DC) Investor Relations:Constantin Fest +44 (0) 7831 826525 (London)James Dodwell +44 (0) 20 8047 2406 (London)Mick Readey +44 (0) 7990 339653 (London)Steph Mountifield +44 (0) 7796 707505 (London)Jeff McLaughlin +1 215 751 7002 (Philadelphia)Frannie DeFranco +1 215 751 3126 (Philadelphia) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
Grant funding will be provided to support national, state, and local non-profit organizations and community-based groups focused on lupus New resources and tools will support implementation of community-led programs designed to improve earlier diagnosis, enhance awareness of and access to evidence-based treatment, and/or advance communication between patients and providers Deadline for proposals is September 1, 2025 PHILADELPHIA, June 16, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). "Too many people living with lupus face delays in diagnosis and disconnects in care," said Court Horncastle, Senior Vice President at GSK. "With this initiative, we're proud to support the organizations working within local communities to improve diagnosis, access to optimal care, and connection for those impacted by lupus." GSK is seeking proposals for community-driven initiatives aimed at improving earlier diagnosis and recognition of lupus signs and symptoms; enhancing awareness of and access to evidence-based treatment options; and/or advancing communication between patients and providers regarding lupus. GSK is committing up to $1 million USD in grant funding to support national, state, and local non-profit organizations and community-based groups focused on lupus. This program is in addition to existing funding opportunities GSK provides to support the critical work of partner organizations within the lupus ecosystem. GSK recognizes the pivotal leadership demonstrated by these types of groups and the need to sustain their important work as patient advocates. Eligible organizations should respond to the Call for Grant Applications (CGA) with programming that aligns with the Linked by Lupus: Optimal Care Initiative mission to support people impacted by lupus and help create a sustainable lupus community that fosters a sense of belonging, shared understanding, and mutual support among patients and care partners in the US. Grant proposals are due by September 1, 2025 and will be reviewed and approved according to set principles and criteria. To receive the principles and criteria, please email The grant application process is now open on When submitting your request, please use the following format in your project title: Linked by Lupus: [insert your grant title]. GSK will coordinate regular convenings with external stakeholders and harness existing forums to share best practices in addressing health inequities in lupus, empowering public health organizations and communities with actionable models to help bring successful efforts to scale. More information is available at About GSKGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. Registered in England & Wales:No. 3888792 Registered Office:79 New Oxford StreetLondonWC1A 1DG View source version on Contacts GSK inquiriesMedia:Tim Foley +44 (0) 20 8047 5502 (London)Dan Smith +44 (0) 20 8047 5502 (London)Kathleen Quinn +1 202 603 5003 (Washington DC)Lyndsay Meyer +1 202 302 4595 (Washington DC) Investor Relations:Constantin Fest +44 (0) 7831 826525 (London)James Dodwell +44 (0) 20 8047 2406 (London)Mick Readey +44 (0) 7990 339653 (London)Steph Mountifield +44 (0) 7796 707505 (London)Jeff McLaughlin +1 215 751 7002 (Philadelphia)Frannie DeFranco +1 215 751 3126 (Philadelphia) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
7 hours ago
- Business Wire
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). 'Too many people living with lupus face delays in diagnosis and disconnects in care,' said Court Horncastle, Senior Vice President at GSK. 'With this initiative, we're proud to support the organizations working within local communities to improve diagnosis, access to optimal care, and connection for those impacted by lupus.' GSK is seeking proposals for community-driven initiatives aimed at improving earlier diagnosis and recognition of lupus signs and symptoms; enhancing awareness of and access to evidence-based treatment options; and/or advancing communication between patients and providers regarding lupus. GSK is committing up to $1 million USD in grant funding to support national, state, and local non-profit organizations and community-based groups focused on lupus. This program is in addition to existing funding opportunities GSK provides to support the critical work of partner organizations within the lupus ecosystem. GSK recognizes the pivotal leadership demonstrated by these types of groups and the need to sustain their important work as patient advocates. Eligible organizations should respond to the Call for Grant Applications (CGA) with programming that aligns with the Linked by Lupus: Optimal Care Initiative mission to support people impacted by lupus and help create a sustainable lupus community that fosters a sense of belonging, shared understanding, and mutual support among patients and care partners in the US. Grant proposals are due by September 1, 2025 and will be reviewed and approved according to set principles and criteria. To receive the principles and criteria, please email The grant application process is now open on When submitting your request, please use the following format in your project title: Linked by Lupus: [insert your grant title]. GSK will coordinate regular convenings with external stakeholders and harness existing forums to share best practices in addressing health inequities in lupus, empowering public health organizations and communities with actionable models to help bring successful efforts to scale. More information is available at About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the 'Risk Factors' section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. Registered in England & Wales: No. 3888792 Registered Office: 79 New Oxford Street London WC1A 1DG
